-transparent.png){kind=logo}
OBJECTIVE We conducted a single-centre, randomised, double-blinded, placebo-controlled phase II clinical study to test safety and efficacy of a 12-week therapy with low-dose (700 mg/daily) or high-dose (2800 mg/daily) of NAC. METHODS Twenty-one patients (DeltaF508 homo/heterozygous, FEV1>40% pred.) were included in the study. After a 3-weeks placebo run-in phase, 11 patients received low-dose NAC, and 10 patients received high-dose NAC. Outcomes included safety and clinical parameters, inflammatory (total leukocyte numbers, cell differentials, TNF-alpha, IL-8) measures in induced sputum, and concentrations of extracellular glutathione in induced sputum and blood. RESULTS High-dose NAC was a well-tolerated and safe medication. High-dose NAC did not alter clinical or inflammatory parameters. However, extracellular glutathione in induced sputum tended to increase on high-dose NAC. CONCLUSIONS High-dose NAC is a well-tolerated and safe medication for a prolonged therapy of patients with CF with a potential to increase extracellular glutathione in CF airways.
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
March 2006,
Proceedings of the National Academy of Sciences of the United States of America,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
May 2007,
Critical care medicine,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
June 2016,
Therapeutic advances in drug safety,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
January 2020,
PloS one,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
February 2022,
The European respiratory journal,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
May 2016,
Respiratory investigation,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
March 2015,
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
January 2015,
BMJ open respiratory research,
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
January 1999,
Acta paediatrica (Oslo, Norway : 1992),
N Dauletbaev, and
P Fischer, and
B Aulbach, and
J Gross, and
W Kusche, and
U Thyroff-Friesinger, and
T O F Wagner, and
J Bargon
October 2019,
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
